Disrupting the paradigm

As a woman-founded and led company with in-house manufacturing capabilities of its internally conceived portfolio of products, Femasys is well-positioned to deliver its solutions to the market with the achievement of global regulatory approvals.

Dov Elefant

Chief Financial Officer

Mr. Elefant has more than 25 years of industry experience at both public and private healthcare companies. He has a proven record as a senior level global financial expert with financial reporting, fundraising, and mergers and acquisitions expertise. Most recently, he was the vice president and CFO of Cellectar Biosciences, a publicly traded late-stage clinical biopharmaceutical company focused on targeted cancer drugs. Before that, Mr. Elefant served as CFO of Celsus Therapeutics, a publicly traded biopharmaceutical company, until its acquisition of Swiss company, Volution Immuno Pharmaceuticals in 2015, when it was then renamed Akari Therapeutics Plc. Prior to this, Mr. Elefant was CFO at Althera Medical Ltd, a medical device company focused on cancer therapies. Earlier in his career, he led business operations, including overseeing equity and debt financings and licensing deals, for various other finance departments at Lev Pharmaceuticals through its acquisition by ViroPharma in 2009, EpiCept Corporation, Alteon, Inc. and Innapharma, Inc. Mr. Elefant is a graduate of Yeshiva University with a B.S. in Accounting.